• 1
    Lee W. Drug-induced hepatotoxicity. N Engl J Med 2003; 349: 474485.
  • 2
    Zimmerman HJ. Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver. 2nd ed. Philadelphia: Lippincott Williams & Wilkins, Philadelphia, 1999.
  • 3
    Bissell DM, Gores GJ, Laskin D, Hoofnagle JH. Drug-induced liver injury: mechanisms and test systems. HEPATOLOGY 2001; 33: 10091013.
  • 4
    Delves PJ, Roitt I. The immune system. First of two parts. N Engl J Med 2000; 343: 3749.
  • 5
    Park BK, Kitteringham NR, Powell H, Pirmohamed M. Advances in molecular toxicology—towards understanding idiosyncratic drug toxicity. Toxicology 2000; 153: 3960.
  • 6
    Stricker BH, Block R, Claas FH, Parys GE, Desmet VJ. Hepatic injury associated with the use of nitrofurans: a clinicopathological study of 52 reported cases. HEPATOLOGY 1988; 8: 599606.
  • 7
    Berson A, Freneaux E, Larrey D, Lepage V, Douay C, Mallet C, et al. Possible role of HLA in hepatotoxicity. An exploratory study in 71 patients with drug-induced idiosyncratic hepatitis. J Hepatol 1994; 20: 336342.
  • 8
    Hautekeete ML, Horsmans Y, Van Waeyenberge C, Demanet C, Henrion J, Verbist L, et al. HLA association of amoxicillin-clavulanate-induced hepatitis. Gastroenterology 1999; 117: 11811186.
  • 9
    O'Donohue J, Oien KA, Donaldson P, Underhill J, Clare M, MacSween RN, et al. Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut 2000; 47: 717720.
  • 10
    Andrade RJ, Lucena MI, Martin-Vivaldi R, Fernandez MC, Nogueras F, Pelaez G, et al. Acute liver injury associated with the use of ebrotidine, a new H2-receptor antagonist. J Hepatol 1999; 31: 641646.
  • 11
    Danan G, Bénichou C. Causality assessment of adverse reactions to drugs I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993; 46: 13231330.
  • 12
    Lucena MI, Camargo R, Andrade RJ, Perez-Sanchez C, Sanchez de la Cuesta F. Comparison of two clinical scales for causality assessment in hepatotoxicity. HEPATOLOGY 2001; 33: 123130.
  • 13
    Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990; 11: 272276.
  • 14
    World Health Organisation Collaborating Centre for Drug Statistics Methodology. Anatomical therapeutic chemical (ATC) classification index including defined daily dose (DDDs) for plain substances. Oslo: World Health Organisation; 1997.
  • 15
    Martinez-Laso J, De Juan D, Martinez-Quiles N, Gomez-Casado E, Cuadrado E, Arnaiz-Villena A. The contribution of the HLA-A, -B, -C and –DR, -DQ DNA typing to the study of the origins of Spaniards and Basques. Tissue Antigens 1995; 45: 237245.
  • 16
    Ramal LM, de Pablo R, Gaudix MJ, Sanchez J, Garrido A, Garrido F et al. HLA class II allele distribution in the Gypsy community of Andalusia, southern Spain. Tissue Antigens 2001; 57: 138143.
  • 17
    Kaplowitz N. Drug-induced liver disorders: introduction and overview. In: KaplowitzN, DeLeveLD, eds. Drug-Induced Liver Disease. New York: Marcel Dekker, 2003: 114.
  • 18
    García Ruiz E, Andrade R y Grupo de Estudio de Hepatopatías asociadas a medicamentos. Hepatopatías tóxicas: análisis de las incidencias remitidas a un registro en el período 1994-2002 [Abstract]. Rev Esp Enferm Dig 2003; 95(Suppl): 29.
  • 19
    Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Sem Liver Dis 2002; 22: 145155.
  • 20
    Kaplowitz N. Drug-induced hepatocellular injury and cholestasis. In: AASLD Postgraduate course. Mechanism of acute and chronic liver disease: implications for diagnosis, pathogenesis and treatment. Boston, MA: AASLD; 2002: 7986.
  • 21
    Miyamori H, Kato Y, Kobayashi K, Hattori N. HLA antigens in Japanese patients with primary biliary cirrhosis and autoimmune hepatitis. Digestion 1983; 26: 213217.
  • 22
    Donaldson PT, Farrant JM, Wilkinson ML, Hayllar K, Portmann BC, Williams R. Dual association of HLA DR2 and DR3 with primary sclerosing cholangitis. HEPATOLOGY 1991; 13: 129133.
  • 23
    Manns MM, Kruger M. Immunogenetics of chronic liver diseases. Gastroenterology 1994; 106: 16761697.
  • 24
    Yasoshima M, Nakanuma Y, Tsuneyama K, Van de Water J, Gershwin ME. Immunohistochemical analysis of adhesion molecules in the microenvironment of portal tracts in relation to aberrant expression of PDC-E2 and HLA-DR on the bile ducts in primary biliary cirrhosis. J Pathol 1995; 175: 319325.
  • 25
    Barbatis C, Kelly P, Greveson J, Heryet A, McGee JO. Immunocytochemical analysis of HLA class II (DR) antigens in liver disease in man. J Clin Pathol 1987; 40: 879884.
  • 26
    Sharma SK, Balamurugan A, Saha PK, Pandey RM, Mehra NK. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med 2002; 166: 916919.
  • 27
    Pham BN, Bemuau J, Durand F, Sauvanet A, Degott C, Prin L, et al. Eotaxin expression and eosinophil infiltrate in the liver of patients with drug-induced liver disease. J Hepatol 2001; 34: 537547.
  • 28
    Larrey D. Drug-induced liver diseases. J Hepatol 2000; 32(Suppl 1): 7788.
  • 29
    Maria VA, Victorino RM. Immunological investigation in hepatic drug reactions. Clin Exp Allergy 1998; 28(Suppl 4): 7177.